Stadler Pia-Charlotte, Marsela Enklajd, Kämmerer Till, Frommherz Leonie H, Clanner-Engelshofen Benjamin, French Lars E, Oppel Eva, Reinholz Markus
Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany.
Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA.
Allergol Immunopathol (Madr). 2022 Mar 1;50(2):124-130. doi: 10.15586/aei.v50i2.525. eCollection 2022.
Allergic diseases represent a major global health issue with more than one-third of the global population affected by at least one allergic condition. Allergic conditions can not only cause life-threatening anaphylactic reactions but also impact daily life with a significant influence on mental health and the quality of life (QoL).
This study aims to evaluate the health-related QoL and depression severity among patients presenting in a tertiary care allergy center.
A cross-sectional study was conducted among 596 patients presenting with allergic symptoms or previously diagnosed allergies between October 2018 and April 2019.Patients were screened for depression and the QoL impairment by using three validated scales: the Beck Depression Inventory (BDI), the Dermatologic Life Quality Index (DLQI), and the three-level version of the EuroQol 5-Dimensional (EQ-5D-3L) scale.
One-third (34.8%) of the study population was male and two-thirds (65.2%) were female. About 73.7% (n = 427/579) of the patients suffered from at least one previously diagnosed allergic disease, most frequently to pollen (37.0%, n = 214/579) and food (27.3%, n = 158/579), and 20.0 % (n = 116/579) suffered from urticaria. About 19.3% of the total population suffered from depression. Urticaria, as well as insect venom, food/food additives, and drug allergies significantly affected the QoL and depression severity (p < 0.001), reflected by higher DLQI and BDI scores, and lower scores in the EQ5D-3L index.
Our results provide evidence for a possible correlation of allergies (e.g. against insect venom, food/food additives, and drugs) and/or urticaria with a reduced QoL and a higher depression rate. Patients particularly indicated restrictions for the dimensions, pain/discomfort as well as anxiety/depression. It might be beneficial to implement a standardized questionnaire as a regular screening method for evaluating the mental health status of patients with allergies and/or urticaria.
过敏性疾病是一个重大的全球健康问题，全球超过三分之一的人口至少患有一种过敏症。过敏症不仅会引发危及生命的过敏反应，还会影响日常生活，对心理健康和生活质量（QoL）产生重大影响。
本研究旨在评估三级护理过敏中心患者的健康相关生活质量和抑郁严重程度。
2018年10月至2019年4月期间，对596名有过敏症状或先前被诊断为过敏的患者进行了一项横断面研究。使用三种经过验证的量表对患者进行抑郁和生活质量损害筛查：贝克抑郁量表（BDI）、皮肤病生活质量指数（DLQI）和欧洲五维健康量表三级版本（EQ-5D-3L）。
研究人群中三分之一（34.8%）为男性，三分之二（65.2%）为女性。约73.7%（n = 427/579）的患者至少患有一种先前诊断的过敏性疾病，最常见的是花粉过敏（37.0%，n = 214/579）和食物过敏（27.3%，n = 158/579），20.0%（n = 116/579）的患者患有荨麻疹。约19.3%的总人口患有抑郁症。荨麻疹以及昆虫毒液、食物/食物添加剂和药物过敏显著影响生活质量和抑郁严重程度（p < 0.001），表现为DLQI和BDI得分较高，EQ5D-3L指数得分较低。
我们的结果为过敏（如对昆虫毒液、食物/食物添加剂和药物）和/或荨麻疹与生活质量降低和抑郁率升高之间可能存在的相关性提供了证据。患者特别指出在疼痛/不适以及焦虑/抑郁方面存在限制。实施标准化问卷作为评估过敏和/或荨麻疹患者心理健康状况的常规筛查方法可能会有所帮助。
